The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS).
 
Mrinal M. Gounder
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Karyopharm Therapeutics
Speakers' Bureau - Amgen
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo
 
Andrew J. Wagner
No Relationships to Disclose
 
Neeta Somaiah
Honoraria - Immune Design
Travel, Accommodations, Expenses - Immune Design
 
Richard F. Riedel
No Relationships to Disclose
 
Gary K. Schwartz
Honoraria - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis
 
Steven Attia
Consulting or Advisory Role - EMD Serono; Gradalis; Karyopharm Therapeutics
Research Funding - AB Science (Inst); Bayer (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Morphotek (Inst); Novartis (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst); ZIOPHARM Oncology (Inst)
 
Albiruni R.A. Razak
No Relationships to Disclose
 
Lee D. Cranmer
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Merck
Research Funding - Amgen; Bristol-Myers Squibb; CytRx Corporation; GlaxoSmithKline; Merck; Prometheus; Threshold Pharmaceuticals
 
Scott H. Okuno
No Relationships to Disclose
 
Mohammed M. Milhem
No Relationships to Disclose
 
Cassandra Choe-Juliak
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Michael G. Kauffman
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sant P. Chawla
No Relationships to Disclose